TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported positive preclinical results with its immunotherapy candidate, , in pancreatic adenocarcinoma.

After two weekly treatments with TTX-siPDL1 combined with the standard-of-care chemotherapeutic, gemcitabine, tumor volumes were 25% of those in untreated animals. By the fifth week of treatment, 75% of animals treated with TTX-siPDL1 plus gemcitabine were still alive versus 25% of those that were treated with gemcitabine alone. This is the second drug candidate from TransCode’s platform to show positive preclinical results in pancreatic cancer. The animal model used in this latest study involving TransCode’s siRNA immunotherapy candidate involved implantation of a highly aggressive murine cell line directly into the pancreata of recipient mice. Body weight and histopathology assessments provided preliminary evidence that the treatment was tolerated. Finally, immune cell profiling of tumors from the treated animals indicated successful PD-L1 inhibition and immune cell activation, consistent with the known mechanism-of-action (MOA) of checkpoint inhibitors. Because TTX-siPDL1 incorporates a siRNA against PD-L1 as its functional component, it has the potential to trigger the degradation and/or translational repression of the PD-L1 messenger RNA (mRNA), preventing the cell from expressing the PD-L1 antigen.

Pancreatic cancer has proven difficult to treat with conventional drugs and has been resistant to initial immunotherapy approaches. The reason pancreatic cancer is challenging to treat with immunotherapy is in part due to the presence of a thick fibrous corona surrounding the tumor. In human pancreatic ductal adenocarcinoma, or PDAC, up to 90% of the total volume of the tumor is represented by fibrous tissue, inhibiting access of therapeutics and immune cells into the tumor.

“This is yet another opportunity to showcase our TTX platform which is designed to overcome challenges faced by existing lipid and liposomal systems in delivering RNA therapeutics inside tumor cells and metastatic sites. Demonstrating the ability to deliver RNA therapeutics inside tumors and metastases and to affect documented targets for cancer treatment that have remained undruggable until now using an RNA approach represents a major opportunity for our company,” indicated , CEO and co-founder of TransCode.

, TransCode’s CTO and scientific co-founder, indicated that “the TTX delivery platform has already been shown in our preclinical studies to successfully deliver RNA therapeutics to oncology targets, including using small interfering RNAs, antisense oligonucleotides, and non-coding RNA mimics. Recent updates to our company website include an animation that showcases our delivery platform as well as the MOA of our lead therapeutic candidate, TTX-MC138.”

Medarova continued, “We are looking forward to moving into the clinic to evaluate our therapeutic candidates in patients and to potentially translate our preclinical success to cancer patients around the world.”

The study was conducted in collaboration with Dr. Byunghee Yoo, a faculty member of the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital and Harvard Medical School. The Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital is one of the world’s premier research centers devoted to development and application of advanced biomedical imaging technologies. The Center is part of the Department of Radiology at Massachusetts General Hospital and affiliated with both Harvard Medical School and the Massachusetts Institute of Technology.

About TransCode Therapeutics

TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totaling over nine million per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Two of the Company’s other drug candidates, TTX-siPDL1 and TTX-siLIN28B, focus on treating tumors by targeting PD-L1 and LIN28B, respectively. TransCode also has three cancer-agnostic programs: TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I, or RIG-I, designed to drive an immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines designed to activate cytotoxic immune responses against tumor cells.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the results of a preclinical study of TTX-siPDL1 in pancreatic adenocarcinoma, statements concerning pancreatic cancer, statements concerning the results of preclinical studies in other tumor types, statements concerning the expected clinical results of TransCode’s therapeutic candidates, statements concerning the ability of TransCode’s TTX platform to deliver RNA therapeutics inside tumors and metastases, statements concerning the results of RNA research, statements concerning the potential for treating cancer with RNA therapeutics, statements concerning the timing and outcome of expected regulatory filings and clinical trials, and statements concerning TransCode’s development programs and TTX technology platform generally. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk associated with drug discovery and development; the risk that the results of our planned clinical trials will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode’s planned regulatory submissions; risks associated with TransCode’s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Annual Report on Form 10-K for the year ended December 31, 2021, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.

For more information, please contact:

TransCode Therapeutics, Inc.

Alan Freidman, VP Investor Relations